Status:
COMPLETED
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic...
Eligibility Criteria
Inclusion
- Men and women age 18 to 65
- Both Eyes present with lenses intact (no previous cataract extractions)
- Stable place of residency
Exclusion
- History of corneal surgery
- Legal blindness (defined as best corrected visual acuity of 20/200 or worse in one or both eyes
- Previous participation in this study
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
1098 Patients enrolled
Trial Details
Trial ID
NCT00206102
Start Date
September 1 2003
End Date
October 1 2008
Last Update
January 14 2013
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Little Rock, Arkansas, United States
2
Research Site
Mabelvale, Arkansas, United States
3
Research Site
Morrilton, Arkansas, United States
4
Research Site
Anaheim, California, United States